These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2300540)

  • 21. Kinetics of hydrochlorothiazide absorption in humans.
    Redalieu E; Chan KK; Tipnis V; Zak SB; Gilleran TG; Wagner WE; LeSher AR
    J Pharm Sci; 1985 Jul; 74(7):765-7. PubMed ID: 4032251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors affecting the error in the Loo-Riegelman method for estimating the rate of drug absorption. Some suggestions for a practical sampling schedule.
    Zeng YL; Akkermans AA; Breimer DD
    Arzneimittelforschung; 1983; 33(5):757-60. PubMed ID: 6688184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral and IV dosing: a method to determine the compartment of drug elimination for two-compartment models.
    Yates JW; Arundel PA
    J Pharm Sci; 2008 Jun; 97(6):2036-40. PubMed ID: 17847075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic modelling of pentoxifylline and lisofylline after oral and intravenous administration in mice.
    Wyska E; Szymura-Oleksiak J; Pekala E; Obruśnik A
    J Pharm Pharmacol; 2007 Apr; 59(4):495-501. PubMed ID: 17430632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extension of the Loo-Riegelman method to pharmacokinetic data at steady state.
    Nüesch EA
    Eur J Clin Pharmacol; 1990; 39(1):55-7. PubMed ID: 2148911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.
    Olsson-Gisleskog P; Jacqmin P; Perez-Ruixo JJ
    Clin Pharmacokinet; 2007; 46(2):159-73. PubMed ID: 17253886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo evaluation of controlled-release products.
    Hwang SS; Bayne W; Theeuwes F
    J Pharm Sci; 1993 Nov; 82(11):1145-50. PubMed ID: 8289130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism.
    Cong D; Doherty M; Pang KS
    Drug Metab Dispos; 2000 Feb; 28(2):224-35. PubMed ID: 10640522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Critical analysis of "flip-flop" phenomenon in two-compartment pharmacokinetic model.
    Byron PR; Notari RE
    J Pharm Sci; 1976 Aug; 65(8):1140-4. PubMed ID: 978432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interpretation of plasma concentration-time curves after oral dosing.
    Ronfeld RA; Benet LZ
    J Pharm Sci; 1977 Feb; 66(2):178-80. PubMed ID: 839412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A linear model for the pharmacokinetics of azithromycin in healthy volunteers.
    Ripa S; Ferrante L; Prenna M
    Chemotherapy; 1996; 42(6):402-9. PubMed ID: 8957574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Wagner-Nelson method applied to a multicompartment model with zero order input.
    Wagner JG
    Biopharm Drug Dispos; 1983; 4(4):359-73. PubMed ID: 6661514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of variability in explaining ethanol pharmacokinetics: research and forensic applications.
    Norberg A; Jones AW; Hahn RG; Gabrielsson JL
    Clin Pharmacokinet; 2003; 42(1):1-31. PubMed ID: 12489977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of oral sustained release clonidine in humans.
    MacGregor TR; Relihan GL; Keirns JJ
    Arzneimittelforschung; 1985; 35(1A):440-6. PubMed ID: 4039184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimation of the rate constants in a data-sparse environment: comparison of a mathematical method and least squares analysis.
    Barcia EM; Newburger J; Young D
    J Pharm Sci; 1988 Feb; 77(2):175-7. PubMed ID: 3361434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel method to estimate the absorption rate constant for two-compartment model fitted drugs without intravenous pharmacokinetic data.
    Liu F; Yi H; Wang L; Cheng Z; Zhang G
    Front Pharmacol; 2023; 14():1087913. PubMed ID: 37214472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consequence of equal absorption, distribution and/or elimination rate constants.
    Plusquellec Y; Courbon F; Nogarede S
    Eur J Drug Metab Pharmacokinet; 1999; 24(3):197-203. PubMed ID: 10716057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zidovudine bioavailability and linear pharmacokinetics in female B6C3F1 mice.
    Trang JM; Prejean JD; James RH; Irwin RD; Goehl TJ; Page JG
    Drug Metab Dispos; 1993; 21(1):189-93. PubMed ID: 8095218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetics of onercept in healthy subjects.
    Glatt S; Fuseau E; Buraglio M; Nguyen QT
    Clin Pharmacokinet; 2005; 44(12):1295-304. PubMed ID: 16372827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.